Product Name | HO-1 ELISA Kit |
Description |
Colorimetric detection of heme oxygenase 1 |
Species Reactivity | Human, Rat |
Platform | Microplate |
Sample Types | Cell lysates, Cyst fluid, Serum, Tissue |
Detection Method | Colorimetric Assay |
Assay Type | Sandwich ELISA (Enzyme-linked Immunosorbent Assay) |
Utility | ELISA kit used to quantitate HO-1 concentration in samples. |
Sensitivity | 0.21 ng/ml |
Assay Range | 0.781 - 50 ng/mL |
Incubation Time | 30 minutes |
Number of Samples | 40 samples in duplicate |
Other Resources | Kit Booklet Lot No. SH334100 , Kit Booklet Lot No. SH111999 , Kit Booklet Lot No. SH288446 , Kit Booklet , MSDS |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | 4ºC and -20ºC | |||||||||||||||||||||||||||||||||||||||
Shipping Temperature | Blue Ice | |||||||||||||||||||||||||||||||||||||||
Product Type | ELISA Kits | |||||||||||||||||||||||||||||||||||||||
Assay Overview | 1. Prepare Standard and samples in Standard and Sample Diluent. 2. Add 50 µL of Pre-Treatment Buffer to all sample and standard wells. 3. Add 50 µL of Standard and sample to appropriate wells. 4. Cover plate with Plate Sealer and incubate at room temperature (20-25°C) for 2 hours. 5. Wash plate four times with 1X Wash Buffer. 6. Add 100 µL of Biotinylated Antibody Working Solution to each well. 7. Cover plate with Plate Sealer and incubate at room temperature for 1 hour. 8. Wash plate four times with 1X Wash Buffer as described in step 5. 9. Add 100 µL of Streptavidin-HRP Working Solution to each well. 10. Cover plate with Plate Sealer and incubate at room temperature for 30 minutes. 11. Wash plate four times with 1X Wash Buffer as described in step 5. 12. Add 100 µL of TMB Substrate to each well. 13. Develop the plate in the dark at room temperature for 30 minutes. 14. Stop reaction by adding 100 µL of Stop Solution to each well. 15. Measure absorbance on a plate reader at 450 nm. | |||||||||||||||||||||||||||||||||||||||
Kit Overview |
|
|||||||||||||||||||||||||||||||||||||||
Cite This Product | HO-1 ELISA Kit (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SKT-111) |
Alternative Names | Heme oxygenase 1 ELISA Kit, Hemox ELISA Kit, HMOX1 ELISA Kit, HO1 ELISA Kit, HO 1 ELISA Kit, HSP32 ELISA Kit |
Research Areas | Cancer, Oxidative Stress |
Scientific Background | Heme-oxygenase is a ubiquitous enzyme that catalyzes the initial and rate-limiting steps in heme catabolism yielding equimolar amounts of biliverdin, iron and carbon monoxide. Biliverdin is subsequently converted to bilirubin and the free iron is sequestered to ferritin (1). These products have important physiological effects as carbon monoxide is a potent vasodilator; biliverdin and bilirubin are potent antioxidants; and the free iron increases oxidative stress and regulates the expression of many mRNAs (2). There are three isoforms of heme-oxygenase, HO-1, HO-2 and HO-3; however HO-1 and HO-2 are the major isoforms as they both have been identified in mammals (3). HO-1, also known as heat shock protein 32, is an inducible isoform activated by most oxidative stress inducers, cytokines, inflammatory agents and heat shock. HO-2 is a constitutive isoform which is expressed under homeostatic conditions. HO-1 is also considered to be a cytoprotective factor in that free heme is highly reactive and cytotoxic, and secondly, carbon monoxide is a mediator inhibiting the inflammatory process and bilirubin is a scavenger for reactive oxygen, both of which are the end products of heme catalyzation (4). It has also been shown that HO-1 deficiency may cause reduced stress defense, a pro-inflammatory tendency (5), susceptibility to atherosclerotic lesion formation (6), endothelial cell injury, and growth retardation (7). Up-regulation of HO-1 is therefore said to be one of the major defense mechanisms of oxidative stress (4). |
References |
1. Froh M. et al. (2007) World J. Gastroentereol 13(25): 3478-86. 2. Elbirt K.K. and Bonkovsky H.L. (1999) Proc Assoc Am Physicians 111(5): 348-47. 3. Maines M.D., Trakshel G.M., and Kutty R.K. (1986) J Biol Chem 261: 411–419. 4. Brydun A., et al. (2007) Hypertens Res 30(4): 341-8. 5. Poss K.D. and Tonegawa S. (1997). Proc Natl Acad Sci U S A. 94: 10925–10930. 6. Yet S.F., et al. (2003) FASEB J. 17: 1759–1761. 7. Yachie A., et al. (1999) J Clin Invest. 103: 129–135. |
StressMarq Biosciences :
Based on validation through cited publications.